68 /100
HIGH RISK
Score updated Jul 14, 2026

NMTC — NeuroOne Medical Technologies Corporation Dilution Risk Tracker

Track NMTC dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track NMTC — Get alerts when the score changes →

As of July 14, 2026, NeuroOne Medical Technologies Corporation (NMTC) has a DilutionWatch DilutionScore of 68/100, rated HIGH dilution risk. NeuroOne Medical Technologies Corporation has a market capitalization of $30.60M, 8.70M shares outstanding, 34 institutional holders tracked. Key dilution vectors include approximately 4 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
46
💰 Cash Runway
85
📊 Float Risk
27
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

⛈️
Warning
High probability of dilution event
43%
🔁 Convertible Conversion 60%
• Major convertible overhang: 23562% potential dilution
• Convertible risk score very high (85/100)
💰 Capital Raise 35%
• Low cash runway: 4 months remaining
🔄 Reverse Split 15%
• Only 4 months cash — financial pressure
🔔 Track NMTC — Get forecast alerts →

💹 Market Data

Market Cap$30.60M
Shares Outstanding8.70M
Float7.82M
Cash$3.80M
Debt$121.9K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 6.3% shares (2026Q1 vs prior)
34 institutional holders · 13.36M shares
#1 Bleichroeder LP 4.00M shares
#2 VANGUARD CAPITAL MANAGEMENT LLC 2.79M shares
#3 BARD ASSOCIATES INC 1.84M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest28.8K
Days to Cover1.0
% of Float0.4%
FINRA data as of Jun 30, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Sep 30, 2025
xbrl XBRL CONVERTIBLE Sep 30, 2021
4 INSIDER TRANSACTION Apr 07, 2026
4 INSIDER TRANSACTION Apr 07, 2026
4 INSIDER TRANSACTION Apr 07, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for NMTC Shareholders

NeuroOne Medical Technologies Corporation (NMTC) has a DilutionScore of 68/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

Cash runway is a key watch item: NMTC has approximately 4 months of runway at current burn rate. Companies with less than 18 months of runway are statistically more likely to file new shelf registrations or ATM programs within the next two quarters. DilutionWatch monitors SEC 10-Q filings to update this estimate each quarter.

DilutionWatch tracks over 25 SEC filing types for NMTC in real-time, scanning EDGAR every 60 seconds. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for NMTC alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track NMTC Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking NMTC — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for NMTC
📊 NMTC FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 NMTC Signal Convergence & Dark Pool Activity — StonkWhisper 📄 NMTC Dilution Risk Analysis — Full In-Depth Report

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.